{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T13:35:10Z","timestamp":1787578510276,"version":"build-2736575974"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,15]]},"DOI":"10.7759\/cureus.108901","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T14:51:26Z","timestamp":1778856686000},"source":"Crossref","is-referenced-by-count":1,"title":["Pseudomonas aeruginosa in Ventilator-Associated Pneumonia: A Comprehensive Review of Resistance and Clinical Outcomes"],"prefix":"10.7759","author":[{"given":"Sneha  D","family":"Parit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka M","family":"Mane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satish R","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_201902_17020","article-title":"The role of the hospital environment in the healthcare-associated infections: a general review of the literature","volume":"23","author":"Facciol\u00e0 A","year":"2019","unstructured":"Facciol\u00e0 A, Pellican\u00f2 GF, Visalli G, et al.. The role of the hospital environment in the healthcare-associated infections: a general review of the literature. Eur Rev Med Pharmacol Sci. 2019, 23:1266-78. 10.26355\/eurrev_201902_17020","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.idh.2017.07.001","article-title":"The burden of healthcare-associated infection in Australian hospitals: a systematic review of the literature","volume":"22","author":"Mitchell BG","year":"2017","unstructured":"Mitchell BG, Shaban RZ, MacBeth D, Wood CJ, Russo PL. The burden of healthcare-associated infection in Australian hospitals: a systematic review of the literature. Infect Dis Health. 2017, 22:117-28. 10.1016\/j.idh.2017.07.001","journal-title":"Infect Dis Health"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1017\/ice.2018.183","article-title":"The preventable proportion of healthcare-associated infections 2005-2016: systematic review and meta-analysis","volume":"39","author":"Schreiber PW","year":"2018","unstructured":"Schreiber PW, Sax H, Wolfensberger A, Clack L, Kuster SP. The preventable proportion of healthcare-associated infections 2005-2016: systematic review and meta-analysis. Infect Control Hosp Epidemiol. 2018, 39:1277-95. 10.1017\/ice.2018.183","journal-title":"Infect Control Hosp Epidemiol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1590\/0034-7167-2019-0477","article-title":"Education to prevent ventilator-associated pneumonia in intensive care unit","volume":"73","author":"Branco A","year":"2020","unstructured":"Branco A, Louren\u00e7one EM, Monteiro AB, Fonseca JP, Blatt CR, Caregnato RC. Education to prevent ventilator-associated pneumonia in intensive care unit. Rev Bras Enferm. 2020, 73:e20190477. 10.1590\/0034-7167-2019-0477","journal-title":"Rev Bras Enferm"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejccm.2017.06.001","article-title":"Ventilator-associated pneumonia in adult intensive care unit prevalence and complications","volume":"5","author":"Othman AA","year":"2017","unstructured":"Othman AA, Abdelazim MS. Ventilator-associated pneumonia in adult intensive care unit prevalence and complications. Egypt J Crit Care Med. 2017, 5:61-3. 10.1016\/j.ejccm.2017.06.001","journal-title":"Egypt J Crit Care Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e3325","article-title":"Ventilator associated pneumonia","volume":"344","author":"Hunter JD","year":"2012","unstructured":"Hunter JD. Ventilator associated pneumonia. BMJ. 2012, 344:e3325. 10.1136\/bmj.e3325","journal-title":"BMJ"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s100960000236","article-title":"Analysis of risk factors for ventilator-associated pneumonia in a multidisciplinary intensive care unit","volume":"19","author":"Sofianou DC","year":"2000","unstructured":"Sofianou DC, Constandinidis TC, Yannacou M, Anastasiou H, Sofianos E. Analysis of risk factors for ventilator-associated pneumonia in a multidisciplinary intensive care unit. Eur J Clin Microbiol Infect Dis. 2000, 19:460-3. 10.1007\/s100960000236","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2008.02.001","article-title":"Ventilator-associated pneumonia caused by multidrug-resistant organisms or Pseudomonas aeruginosa: prevalence, incidence, risk factors, and outcomes","volume":"23","author":"Parker CM","year":"2008","unstructured":"Parker CM, Kutsogiannis J, Muscedere J, Cook D, Dodek P, Day AG, Heyland DK. Ventilator-associated pneumonia caused by multidrug-resistant organisms or Pseudomonas aeruginosa: prevalence, incidence, risk factors, and outcomes. J Crit Care. 2008, 23:18-26. 10.1016\/j.jcrc.2008.02.001","journal-title":"J Crit Care"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1086\/339488","article-title":"Pseudomonas aeruginosa ventilator-associated pneumonia: comparison of episodes due to piperacillin-resistant versus piperacillin-susceptible organisms","volume":"34","author":"Trouillet JL","year":"2002","unstructured":"Trouillet JL, Vuagnat A, Combes A, Kassis N, Chastre J, Gibert C. Pseudomonas aeruginosa ventilator-associated pneumonia: comparison of episodes due to piperacillin-resistant versus piperacillin-susceptible organisms. Clin Infect Dis. 2002, 34:1047-54. 10.1086\/339488","journal-title":"Clin Infect Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S177247","article-title":"Health care-associated infections - an overview","volume":"11","author":"Haque M","year":"2018","unstructured":"Haque M, Sartelli M, McKimm J, Abu Bakar M. Health care-associated infections - an overview. Infect Drug Resist. 2018, 11:2321-33. 10.2147\/IDR.S177247","journal-title":"Infect Drug Resist"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.4103\/0300-1652.103543","article-title":"Healthcare - associated infections: a public health problem","volume":"53","author":"Revelas A","year":"2012","unstructured":"Revelas A. Healthcare - associated infections: a public health problem. Niger Med J. 2012, 53:59-64. 10.4103\/0300-1652.103543","journal-title":"Niger Med J"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/cc13775","article-title":"Ventilator-associated pneumonia in the ICU","volume":"18","author":"Kalanuria AA","year":"2014","unstructured":"Kalanuria AA, Ziai W, Mirski M. Ventilator-associated pneumonia in the ICU. Crit Care. 2014, 18:208. 10.1186\/cc13775","journal-title":"Crit Care"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.22159\/ijcpr.2024v16i2.4049","article-title":"Bacteriological study of ventilator-associated pneumonia and antibiotic susceptibility of isolates","volume":"16","author":"Kanipakam VK","year":"2024","unstructured":"Kanipakam VK, Thoti H, Sharabu Y, Valluri AL, Gunti R. Bacteriological study of ventilator-associated pneumonia and antibiotic susceptibility of isolates. Int J Curr Pharm Res. 2024, 16:112-6. 10.22159\/ijcpr.2024v16i2.4049","journal-title":"Int J Curr Pharm Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/bjaed\/mkv046","article-title":"Ventilator-associated pneumonia","volume":"16","author":"Gunasekera P","year":"2016","unstructured":"Gunasekera P, Gratrix A. Ventilator-associated pneumonia. Bja Education. 2016, 16:198-202. 10.1093\/bjaed\/mkv046","journal-title":"Bja Education"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-025-03932-2","article-title":"Risk factors and outcomes of ventilator-associated pneumonia: an updated systematic review and meta-analysis","volume":"25","author":"Ochoa P","year":"2025","unstructured":"Ochoa P, Mendoza AR, Molano D, Masclans JR, Parada-Gereda HM. Risk factors and outcomes of ventilator-associated pneumonia: an updated systematic review and meta-analysis. BMC Pulm Med. 2025, 25:453. 10.1186\/s12890-025-03932-2","journal-title":"BMC Pulm Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjid.2015.03.009","article-title":"Spread of multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa clones in patients with ventilator-associated pneumonia in an adult intensive care unit at a university hospital","volume":"19","author":"Royer S","year":"2015","unstructured":"Royer S, Faria AL, Seki LM, et al.. Spread of multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa clones in patients with ventilator-associated pneumonia in an adult intensive care unit at a university hospital. Braz J Infect Dis. 2015, 19:350-7. 10.1016\/j.bjid.2015.03.009","journal-title":"Braz J Infect Dis"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1462-2920.2009.02041.x","article-title":"The Pseudomonas story","volume":"12","author":"Palleroni NJ","year":"2010","unstructured":"Palleroni NJ. The Pseudomonas story. Environ Microbiol. 2010, 12:1377-83. 10.1111\/j.1462-2920.2009.02041.x","journal-title":"Environ Microbiol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-012-1758-8","article-title":"Impact of multidrug resistance on Pseudomonas aeruginosa ventilator-associated pneumonia outcome: predictors of early and crude mortality","volume":"32","author":"Pe\u00f1a C","year":"2013","unstructured":"Pe\u00f1a C, G\u00f3mez-Zorrilla S, Oriol I, Tubau F, Dominguez MA, Pujol M, Ariza J. Impact of multidrug resistance on Pseudomonas aeruginosa ventilator-associated pneumonia outcome: predictors of early and crude mortality. Eur J Clin Microbiol Infect Dis. 2013, 32:413-20. 10.1007\/s10096-012-1758-8","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"ref19","doi-asserted-by":"crossref","DOI":"10.18869\/modares.iem.2.1.25","article-title":"Pseudomonas aeruginosa: a review of their pathogenesis and prevalence in clinical settings and the environment","volume":"2","author":"Streeter K","year":"2016","unstructured":"Streeter K, Katouli M. Pseudomonas aeruginosa: a review of their pathogenesis and prevalence in clinical settings and the environment. Infect Epidemiol Med. 2016, 2:25-32.","journal-title":"Infect Epidemiol Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(10)70089-X","article-title":"Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases","author":"Bennett JE","year":"2015","unstructured":"Bennett JE, Dolin R, Blaser MJ. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Saunders, Philadelphia, PA; 2015. 10.1016\/S1473-3099(10)70089-X"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/4230397","article-title":"Antimicrobial potential of extract from a Pseudomonas aeruginosa isolate","volume":"2022","author":"Amankwah FK","year":"2022","unstructured":"Amankwah FK, Gbedema SY, Boakye YD, Bayor MT, Boamah VE. Antimicrobial potential of extract from a Pseudomonas aeruginosa isolate. Scientifica (Cairo). 2022, 2022:4230397. 10.1155\/2022\/4230397","journal-title":"Scientifica (Cairo)"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-015-0926-5","article-title":"An international multicenter retrospective study of Pseudomonas aeruginosa nosocomial pneumonia: impact of multidrug resistance","volume":"19","author":"Micek ST","year":"2015","unstructured":"Micek ST, Wunderink RG, Kollef MH, et al.. An international multicenter retrospective study of Pseudomonas aeruginosa nosocomial pneumonia: impact of multidrug resistance. Crit Care. 2015, 19:219. 10.1186\/s13054-015-0926-5","journal-title":"Crit Care"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268810003055","article-title":"Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: risk factors and mortality","volume":"139","author":"Tumbarello M","year":"2011","unstructured":"Tumbarello M, Repetto E, Trecarichi EM, et al.. Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: risk factors and mortality. Epidemiol Infect. 2011, 139:1740-9. 10.1017\/S0950268810003055","journal-title":"Epidemiol Infect"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society","volume":"63","author":"Kalil AC","year":"2016","unstructured":"Kalil AC, Metersky ML, Klompas M, et al.. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016, 63:e61-111. 10.1093\/cid\/ciw353","journal-title":"Clin Infect Dis"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.37201\/req\/s03.06.2022","article-title":"Current treatment of nosocomial pneumonia and ventilator-associated pneumonia","volume":"35 Suppl 3","author":"Plata-Menchaca EP","year":"2022","unstructured":"Plata-Menchaca EP, Ferrer R. Current treatment of nosocomial pneumonia and ventilator-associated pneumonia. Rev Esp Quimioter. 2022, 35 Suppl 3:25-9. 10.37201\/req\/s03.06.2022","journal-title":"Rev Esp Quimioter"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30403-7","article-title":"Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial","volume":"19","author":"Kollef MH","year":"2019","unstructured":"Kollef MH, Nov\u00e1\u010dek M, Kivistik \u00dc, et al.. Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2019, 19:1299-311. 10.1016\/S1473-3099(19)30403-7","journal-title":"Lancet Infect Dis"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30731-3","article-title":"Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial","volume":"21","author":"Wunderink RG","year":"2021","unstructured":"Wunderink RG, Matsunaga Y, Ariyasu M, et al.. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2021, 21:213-25. 10.1016\/S1473-3099(20)30731-3","journal-title":"Lancet Infect Dis"},{"key":"ref28","unstructured":"CLSI M100. Performance Standards for Antimicrobial Susceptibility Testing. (2026). Accessed: May 15, 2026: https:\/\/clsi.org\/shop\/standards\/m100\/."},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.eimce.2021.12.017","article-title":"Ceftolozane\/tazobactam for the treatment of Pseudomonas aeruginosa infections: a multicenter case series analysis","volume":"41","author":"Leit\u00e3o IL","year":"2023","unstructured":"Leit\u00e3o IL, Mimoso Santos C, Andr\u00e9 P, Lino S, Lemos M, Froes F. Ceftolozane\/tazobactam for the treatment of Pseudomonas aeruginosa infections: a multicenter case series analysis. Enferm Infecc Microbiol Clin (Engl Ed). 2023, 41:454-61. 10.1016\/j.eimce.2021.12.017","journal-title":"Enferm Infecc Microbiol Clin (Engl Ed)"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00907-24","article-title":"Clinical outcomes and emergence of resistance of Pseudomonas aeruginosa infections treated with ceftolozane-tazobactam versus ceftazidime-avibactam","volume":"68","author":"Hareza DA","year":"2024","unstructured":"Hareza DA, Cosgrove SE, Bonomo RA, et al.. Clinical outcomes and emergence of resistance of Pseudomonas aeruginosa infections treated with ceftolozane-tazobactam versus ceftazidime-avibactam. Antimicrob Agents Chemother. 2024, 68:e0090724. 10.1128\/aac.00907-24","journal-title":"Antimicrob Agents Chemother"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11050579","article-title":"New drugs for the treatment of Pseudomonas aeruginosa infections with limited treatment options: a narrative review","volume":"11","author":"Losito AR","year":"2022","unstructured":"Losito AR, Raffaelli F, Del Giacomo P, Tumbarello M. New drugs for the treatment of Pseudomonas aeruginosa infections with limited treatment options: a narrative review. Antibiotics (Basel). 2022, 11:579. 10.3390\/antibiotics11050579","journal-title":"Antibiotics (Basel)"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.01697-22","article-title":"Antimicrobial activity of ceftolozane-tazobactam, ceftazidime-avibactam, and cefiderocol against multidrug-resistant Pseudomonas aeruginosa recovered at a German university hospital","volume":"10","author":"Weber C","year":"2022","unstructured":"Weber C, Schultze T, G\u00f6ttig S, et al.. Antimicrobial activity of ceftolozane-tazobactam, ceftazidime-avibactam, and cefiderocol against multidrug-resistant Pseudomonas aeruginosa recovered at a German university hospital. Microbiol Spectr. 2022, 10:e0169722. 10.1128\/spectrum.01697-22","journal-title":"Microbiol Spectr"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01390-2","article-title":"Antimicrobial de-escalation in the ICU: from recommendations to level of evidence","volume":"37","author":"Lakbar I","year":"2020","unstructured":"Lakbar I, De Waele JJ, Tabah A, Einav S, Martin-Loeches I, Leone M. Antimicrobial de-escalation in the ICU: from recommendations to level of evidence. Adv Ther. 2020, 37:3083-96. 10.1007\/s12325-020-01390-2","journal-title":"Adv Ther"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","year":"2022","unstructured":"Global burden of bacterial antimicrobial resistance in 2019. a systematic analysis. Lancet. 2022, 399:629-55. 10.1016\/S0140-6736(21)02724-0","journal-title":"Lancet"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa389","article-title":"Lessons learned from the first 10 consecutive cases of intravenous bacteriophage therapy to treat multidrug-resistant bacterial infections at a single center in the United States","volume":"7","author":"Aslam S","year":"2020","unstructured":"Aslam S, Lampley E, Wooten D, Karris M, Benson C, Strathdee S, Schooley RT. Lessons learned from the first 10 consecutive cases of intravenous bacteriophage therapy to treat multidrug-resistant bacterial infections at a single center in the United States. Open Forum Infect Dis. 2020, 7:ofaa389. 10.1093\/ofid\/ofaa389","journal-title":"Open Forum Infect Dis"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1080\/07391102.2023.2202270","article-title":"Targeting the Pseudomonas aeruginosa quorum sensing system to inhibit virulence factors and eradicate biofilm formation using AHL-analogue phytochemicals","volume":"42","author":"Shastry RP","year":"2024","unstructured":"Shastry RP, Abhinand CS. Targeting the Pseudomonas aeruginosa quorum sensing system to inhibit virulence factors and eradicate biofilm formation using AHL-analogue phytochemicals. J Biomol Struct Dyn. 2024, 42:1956-65. 10.1080\/07391102.2023.2202270","journal-title":"J Biomol Struct Dyn"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.635831","article-title":"Rapid antimicrobial susceptibility testing methods for blood cultures and their clinical impact","volume":"8","author":"Banerjee R","year":"2021","unstructured":"Banerjee R, Humphries R. Rapid antimicrobial susceptibility testing methods for blood cultures and their clinical impact. Front Med (Lausanne). 2021, 8:635831. 10.3389\/fmed.2021.635831","journal-title":"Front Med (Lausanne)"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2014.221770","article-title":"MALDI-TOF MS for the diagnosis of infectious diseases","volume":"61","author":"Patel R","year":"2015","unstructured":"Patel R. MALDI-TOF MS for the diagnosis of infectious diseases. Clin Chem. 2015, 61:100-11. 10.1373\/clinchem.2014.221770","journal-title":"Clin Chem"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/480461-pseudomonas-aeruginosa-in-ventilator-associated-pneumonia-a-comprehensive-review-of-resistance-and-clinical-outcomes","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T14:51:37Z","timestamp":1778856697000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/480461-pseudomonas-aeruginosa-in-ventilator-associated-pneumonia-a-comprehensive-review-of-resistance-and-clinical-outcomes"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":38,"URL":"https:\/\/doi.org\/10.7759\/cureus.108901","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,15]]}}}